Evidence mapPaperPMID 36163231Full record

ArticleScientific reports2022

FGF-2 enhances fibrogenetic changes in TGF-β2 treated human conjunctival fibroblasts.

Yuri Tsugeno, Masato Furuhashi, Tatsuya Sato, Megumi Watanabe, Araya Umetsu, Soma Suzuki, Yosuke Ida, Fumihito Hikage, Hiroshi Ohguro

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. FGF2 as a Potential Tumor Suppressor in Lung Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2026
    Article
  3. Inhibition of mTOR differently modulates planar and subepithelial fibrogenesis in human conjunctival fibroblasts.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yuri Tsugeno *Departments of Ophthalmology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Masato Furuhashi *Departments of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Tatsuya Sato *Departments of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Megumi WatanabeDepartments of Ophthalmology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Araya UmetsuDepartments of Ophthalmology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Soma SuzukiDepartments of Ophthalmology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Yosuke IdaDepartments of Ophthalmology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Fumihito HikageDepartments of Ophthalmology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Hiroshi OhguroDepartments of Ophthalmology, Sapporo Medical University School of Medicine, Sapporo, Japan. ooguro@sapmed.ac.jp.
Sapporo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of the current study was to examine the effects of fibroblast growth factor-2 (FGF-2) on conjunctival fibrogenesis that was induced by the presence of transforming growth factor-β2 (TGF-β2). Two-dimension (2D) and three-dimension (3D) cultured human conjunctival fibroblasts (HconF) were used for this purpose. The 2D and 3D cultured HconF were characterized by transendothelial electrical resistance (TEER) and FITC dextran permeability measurements (2D), real-time metabolic analyses (2D), size and stiffness measurements (3D), and the mRNA expression of extracellular matrix molecules, their modulators, Tissue inhibitor of metalloproteinases and matrix metalloproteinases and ER-stress related genes (2D and 3D). FGF-2 significantly increased planar proliferation, as evidenced by TEER values and FITC dextran permeability, and shifted glucose metabolism to the energetic phenotype of 2D HconF cells, and the stiffness of the 3D spheroids, and these effects were further enhanced in the presence of TGF-β2. Analyses of the expression of possible candidate molecules involved in cell architecture and stress indicated that some additive effects caused by both factors were also recognized in some of these molecules. The findings reported herein indicate that the FGF-2, either along or additively with TGF- β2 increased the fibrogenetic changes on the plane as well as in the spatial space of HconF cells.

Indexed as

Fibroblast Growth Factor 2Transforming Growth Factor beta2Cells, CulturedDextransFibroblastsFluorescein-5-isothiocyanateGlucoseHumansMatrix MetalloproteinasesRNA, MessengerTissue Inhibitor of MetalloproteinasesTransforming Growth Factor betaTransforming Growth FactorsDextransFibroblast Growth Factor 2Fluorescein-5-isothiocyanatefluorescein isothiocyanate dextranGlucoseMatrix MetalloproteinasesRNA, MessengerTGFB2 protein, humanTissue Inhibitor of MetalloproteinasesTransforming Growth Factor betaTransforming Growth Factor beta2Transforming Growth Factors

Identifiers

PMID36163231
PMCPMC9512844
OpenAlexW4297224913

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.